Viyash Scientifi

Which are the latest news on Viyash Scientifi?

Why is Viyash Scientific Ltd falling/rising?

As of 24-Jun, Viyash Scientific Ltd's stock price is rising to Rs 271.75, up 2.55%, driven by strong financial results and significant investor confidence. The stock has gained 11.21% over the past week and 30.55% year-to-date, outperforming the Sensex, which has declined.

As of 24-Jun, Viyash Scientific Ltd's stock price is rising, currently at Rs 271.75, reflecting an increase of Rs 6.75 or 2.55%. This upward movement is supported by several positive factors. Over the past week, the stock has gained 11.21%, significantly outperforming the Sensex, which has seen a slight decline of 0.21%. Additionally, the stock has shown impressive year-to-date growth of 30.55%, while the Sensex has dropped by 9.66% during the same period.<BR><BR>The stock's performance is also bolstered by strong financial results, with a remarkable net profit growth of 539.5% reported in March 2026, and consistent positive results over the last nine consecutive quarters. The company's operating profit to interest ratio is at its highest, indicating robust financial health. Furthermore, the stock is trading above its moving averages across various time frames, suggesting a strong upward trend.<BR><BR>Investor participation has also increased, with a delivery volume of 21.75 lacs on June 23, marking a 36.1% rise compared to the five-day average. This indicates growing confidence among investors. The stock is close to its 52-week high, just 2.59% away from Rs 278.8, and it has outperformed its sector by 2.52% today, further contributing to its rising price. Overall, these factors collectively explain the upward movement in Viyash Scientific Ltd's stock price.

How big is Viyash Scientifi?

As of 10th June, Viyash Scientific Ltd has a market capitalization of 11,383.00 Cr, with net sales of 3,070.09 Cr and a net profit of 159.77 Cr reported in the latest four quarters.

As of 10th June, Viyash Scientific Ltd has a market capitalization of 11,383.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, Viyash Scientific reported net sales of 3,070.09 Cr and a net profit of 159.77 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 704.47 Cr and total assets of 1,499.23 Cr.

Who are in the management team of Viyash Scientifi?

The management team of Viyash Scientifi includes N Rajaram (Managing Director & CEO), Sharat Narasapur (Joint Managing Director), and several independent and non-independent directors, along with Krunal Shah as Company Secretary. This diverse team provides strong leadership and expertise to the company.

The management team of Viyash Scientifi includes the following key individuals:<BR><BR>1. **N Rajaram** - Managing Director & CEO<BR>2. **Sharat Narasapur** - Joint Managing Director<BR>3. **Kausalya Santhanam** - Non-Executive & Independent Director<BR>4. **Kamal K Sharma** - Chairman & Independent Director<BR>5. **Milind Sarwate** - Non-Executive & Independent Director<BR>6. **Neeraj Bharadwaj** - Non-Executive & Non-Independent Director<BR>7. **Gregory John Andrews** - Non-Executive & Non-Independent Director<BR>8. **Fabian Kausche** - Non-Executive & Non-Independent Director<BR>9. **Krunal Shah** - Company Secretary & Compliance Officer<BR>10. **Hari Babu Bodepudi** - Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the peers of the Viyash Scientifi?

Viyash Scientifi's peers include Jubilant Pharmo, Alembic Pharma, Concord Biotech, Alivus Life, Marksans Pharma, Shilpa Medicare, Sanofi Consumer, P & G Health Ltd, and Strides Pharma. Viyash has average management risk and a 1-year return of 26.25%, outperforming most peers, while Alembic Pharma and Concord Biotech show strong capital structure ratings.

Peers: The peers of Viyash Scientifi are Jubilant Pharmo, Alembic Pharma, Concord Biotech, Alivus Life, Marksans Pharma, Shilpa Medicare, Sanofi Consumer, P & G Health Ltd, and Strides Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer and P & G Health Ltd, while Good management risk is found at Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma, and Average management risk is present at Jubilant Pharmo and Strides Pharma. Below Average management risk is noted at Shilpa Medicare, while Viyash Scientifi has Average management risk. All peers exhibit Below Average growth except for Alivus Life, Marksans Pharma, Alembic Pharma, and Concord Biotech, which have Below Average growth, while Viyash Scientifi, Shilpa Medicare, and the rest also show Below Average growth. In terms of Capital Structure, Excellent ratings are given to Alembic Pharma, Concord Biotech, and Alivus Life, while Average ratings are seen at Jubilant Pharmo and Strides Pharma, and Below Average ratings are assigned to Viyash Scientifi and Shilpa Medicare.<BR><BR>Return Snapshot: Marksans Pharma has the highest 1-year return at -3.11%, while Concord Biotech has the lowest at -37.68%. Viyash Scientifi's 1-year return is 26.25%, which is significantly higher than both. Additionally, Alembic Pharma, Concord Biotech, and Shilpa Medicare have negative six-month returns.

What does Viyash Scientifi do?

Viyash Scientific Ltd is a small-cap integrated pharmaceutical company, formerly known as Sequent Scientific Limited, with net sales of 920 Cr and a net profit of 52 Cr as of March 2026. Key metrics include a P/E ratio of 59.00 and a market cap of INR 11,383 Cr.

Overview: <BR>Viyash Scientific Ltd is a leading integrated pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap.<BR><BR>History: <BR>The company was originally incorporated as 'P I Drugs & Pharmaceuticals Limited' in 1995 and changed its name to 'Sequent Scientific Limited' in 2009. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 920 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 52 Cr (Quarterly Results - Mar 2026) <BR>Market cap: INR 11,383 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 59.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.08 <BR>Return on Equity: 6.50% <BR>Price to Book: 3.91<BR><BR>Contact Details: <BR>Address: 301 Dosti Pinnacle 3rd Floor, Plot E7 Road No 22 Wagle Indl Thane Maharashtra : 400604 <BR>Tel: 91-022-41114777 <BR>Email: investors@sequent.in <BR>Website: http://www.sequent.in

Are Viyash Scientific Ltd latest results good or bad?

Viyash Scientific Ltd's Q4 FY26 results are strong, with a net profit of ₹52.11 crore (up 459.12% year-on-year) and net sales of ₹919.96 crore (up 129.02%), marking an all-time high. However, concerns about the sustainability of profitability exist due to a high effective tax rate of 47%.

Viyash Scientific Ltd's latest results for Q4 FY26 are quite impressive, indicating a strong turnaround for the company. The net profit reached ₹52.11 crore, a remarkable increase of 459.12% year-on-year, while net sales soared to ₹919.96 crore, reflecting a 129.02% growth compared to the same quarter last year. This performance marks an all-time high in net sales, driven by robust demand in the animal health segment.<BR><BR>The operating margin has also shown significant improvement, standing at 20.03%, which is the highest level since the company's restructuring. This is a notable recovery from the single-digit margins seen in early FY25. Additionally, the profit after tax (PAT) margin increased to 7.22%, up from 2.58% in the same quarter last year.<BR><BR>While the results are strong, there are some concerns regarding the sustainability of this profitability, particularly due to a spike in the effective tax rate to 47%, which is significantly higher than the normalized range. Overall, the financial performance reflects a positive trend, but investors should remain cautious about potential volatility and the company's historical profitability metrics.

Should I buy, sell or hold Viyash Scientific Ltd?

When is the next results date for Viyash Scientific Ltd?

The next results date for Viyash Scientific Ltd is 19 May 2026.

The next results date for Viyash Scientific Ltd is scheduled for 19 May 2026.

Is Sequent Scien. technically bullish or bearish?

As of December 2, 2025, the trend is mildly bullish, supported by bullish MACD indicators and moving averages, but mixed signals from KST and Dow Theory suggest caution.

As of 2 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the weekly and monthly MACD indicators which are both bullish, and the daily moving averages indicating bullish momentum. However, the KST shows a mixed signal with weekly bullishness and monthly mild bearishness, while Dow Theory indicates a mildly bearish stance on the weekly timeframe. The Bollinger Bands also reflect a mildly bullish trend on both weekly and monthly charts. Overall, while there are bullish indicators, the presence of mixed signals suggests caution.

Is Sequent Scien. overvalued or undervalued?

As of December 1, 2025, Sequent Scientific is fairly valued with a PE ratio of 126.16, an EV to EBITDA of 31.90, and a ROCE of 10.17%, despite its higher valuation compared to peers like Cipla and Dr. Reddy's Labs, while achieving a year-to-date return of 25.71%, significantly outperforming the Sensex's 9.60%.

As of 1 December 2025, the valuation grade for Sequent Scientific has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 126.16, an EV to EBITDA of 31.90, and a ROCE of 10.17%. <BR><BR>In comparison to its peers, Sequent Scientific's PE ratio is significantly higher than that of Cipla, which stands at 22.63, and Dr. Reddy's Labs at 18.22, both of which are considered attractive. Despite its high valuation ratios, the company's recent performance shows a year-to-date return of 25.71%, outperforming the Sensex's 9.60%, indicating strong market confidence in its growth potential.

How has been the historical performance of Sequent Scien.?

Sequent Scien. has shown a recovery in profitability and sales growth, with net sales increasing to 1,551.37 Cr in Mar'25 and a net profit of 21.88 Cr, up from a loss the previous year. Key financial metrics indicate a stable position, with improved operating profit and cash flow.

Answer:<BR>The historical performance of Sequent Scien. shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Sequent Scien. has experienced a steady increase in net sales, rising from 1,039.31 Cr in Mar'19 to 1,551.37 Cr in Mar'25, with a notable jump from 1,369.73 Cr in Mar'24. Total operating income followed a similar trajectory, reaching 1,551.37 Cr in Mar'25. However, total expenditure also increased, amounting to 1,389.58 Cr in Mar'25, leading to an operating profit of 161.79 Cr, a significant recovery from the previous year's 61.41 Cr. Profit before tax turned positive at 44.31 Cr in Mar'25 after several years of losses, while profit after tax also improved to 32.26 Cr. The company's net profit stood at 21.88 Cr in Mar'25, a recovery from a loss of 35.88 Cr in Mar'24. The earnings per share (EPS) reflected this positive trend, increasing to 0.87 in Mar'25 from -1.44 in Mar'24. On the balance sheet, total assets rose to 1,499.23 Cr in Mar'25, with total liabilities slightly increasing to 1,499.23 Cr, indicating a stable financial position. Cash flow from operating activities improved to 83.00 Cr in Mar'25, contributing to a closing cash balance of 62.00 Cr. Overall, Sequent Scien. has shown resilience with a recovery in profitability and sales growth, despite challenges in previous years.

Who are the top shareholders of the Sequent Scien.?

The top shareholder of Sequent Scientific is Ca Harbor Investments, holding 52.61%. Other significant shareholders include mutual funds at 10.22%, foreign institutional investors at 6.05%, and individual investors at 23.43%.

The top shareholders of Sequent Scien. include a mix of promoters and institutional investors. The largest shareholder is Ca Harbor Investments, holding 52.61% of the company. Promoters collectively hold a significant majority, with no pledged promoter holdings reported. <BR><BR>In terms of institutional ownership, mutual funds hold 10.22% across eight schemes, while foreign institutional investors (FIIs) account for 6.05% through 54 different entities. The highest public shareholder is Quant Mutual Fund, specifically the Quant Healthcare Fund, which holds 9.53%. Additionally, individual investors collectively own 23.43% of the company.

Has Sequent Scien. declared dividend?

Sequent Scientific Ltd has declared a 25% dividend, amounting to ₹0.5 per share, with an ex-date of September 8, 2021. Despite the dividend declaration, the dividend yield is 0%, and total returns have varied significantly across different periods.

Sequent Scientific Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 0.5<BR>- Ex-date: 08 Sep 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -4.24%, the dividend return was 0%, resulting in a total return of -4.24%.<BR><BR>For the 1-year period, the price return was 55.68%, the dividend return was 0%, leading to a total return of 55.68%.<BR><BR>Over the 2-year period, the price return was 155.28%, with a dividend return of 0%, resulting in a total return of 155.28%.<BR><BR>In the 3-year period, the price return was 74.41%, the dividend return was 0%, which culminated in a total return of 74.41%.<BR><BR>During the 4-year period, the price return was -27.53%, the dividend return was 0.17%, leading to a total return of -27.36%.<BR><BR>For the 5-year period, the price return was 110.09%, the dividend return was 0.52%, resulting in a total return of 110.61%.<BR><BR>Overall, Sequent Scientific Ltd has declared a dividend, but the dividend yield remains at 0%. The total returns over various periods show significant variability, with strong returns in the 1-year and 2-year periods, while the 4-year period experienced a decline.